Disease · MONDO_0005041
Comparisons in its trials53
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 53
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bimatoprost 0.03% Eye Drops vs Latanoprost 0.005% Eye Drops: serious adverse events | 4 of 269 | 11 of 586 | 855 | NCT00541242 | Trial comparisons |
| Bimatoprost 0.01% Ophthalmic Solution vs Bimatoprost 0.03% Ophthalmic Solution: serious adverse events | 45 of 400 | 40 of 398 | 798 | NCT01298700 | Trial comparisons |
| Bimatoprost 0.03% Formulation B Ophthalmic Solution vs Bimatoprost 0.03% Ophthalmic Solution: serious adverse events | 2 of 301 | 5 of 295 | 596 | NCT01099774 | Trial comparisons |
| Bimatoprost/Timolol Formulation A vs Bimatoprost/Timolol Fixed Combination Ophthalmic Solution: serious adverse events | 4 of 278 | 4 of 282 | 560 | NCT01177098 | Trial comparisons |
| T4032 vs Lumigan®: deaths from any cause | 0 of 236 | 0 of 249 | 485 | NCT03825380 | Trial comparisons |
| T4032 vs Lumigan®: serious adverse events | 1 of 236 | 2 of 249 | 485 | NCT03825380 | Trial comparisons |
| Bimatoprost 0.01% vs Bimatoprost 0.03%: serious adverse events | 2 of 233 | 2 of 233 | 466 | NCT01830140 | Trial comparisons |
| DE-117 Ophthalmic Solution vs Timolol Maleate Ophthalmic Solution 0.5%: deaths from any cause | 1 of 204 | 0 of 205 | 409 | NCT03691662 | Trial comparisons |
| DE-117 Ophthalmic Solution vs Timolol Maleate Ophthalmic Solution 0.5%: serious adverse events | 7 of 204 | 1 of 205 | 409 | NCT03691662 | Trial comparisons |
| Bimatoprost vs Travoprost: serious adverse events | 1 of 131 | 0 of 133 | 264 | NCT00440011 | Trial comparisons |
| Bimatoprost vs Travoprost: Tolerability - Conjunctival Hyperemia | 15 of 127 | 22 of 132 | 259 | NCT00440011 | Trial comparisons |
| Tube Shunt Surgery Group vs Trabeculectomy With Mitomycin C: Reoperation for Glaucoma | 21 of 125 | 12 of 117 | 242 | NCT00666237 | Trial comparisons |
| Tube Shunt Surgery Group vs Trabeculectomy With Mitomycin C: deaths from any cause | 5 of 125 | 5 of 117 | 242 | NCT00666237 | Trial comparisons |
| Tube Shunt Surgery Group vs Trabeculectomy With Mitomycin C: serious adverse events | 0 of 125 | 0 of 117 | 242 | NCT00666237 | Trial comparisons |
| T2347 vs Xalacom: serious adverse events | 0 of 127 | 1 of 115 | 242 | NCT02278614 | Trial comparisons |
| Timolol vs Latanoprost: deaths from any cause | 0 of 119 | 0 of 121 | 240 | NCT01677507 | Trial comparisons |
| Timolol vs Latanoprost: serious adverse events | 0 of 119 | 0 of 121 | 240 | NCT01677507 | Trial comparisons |
| Combigan® vs Alphagan® and Timolol Concurrent: serious adverse events | 1 of 120 | 1 of 116 | 236 | NCT01229462 | Trial comparisons |
| Bimatoprost Eye Drops vs Placebo: serious adverse events | 0 of 150 | 0 of 71 | 221 | NCT00538304 | Trial comparisons |
| Combigan® vs Timolol Maleate 0.5%: Number of Subjects With Adverse Events | 15 of 102 | 13 of 102 | 204 | NCT00735449 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005041/comparisons